Morphine and the endogenous opioid peptide ␤-endorphin exert neuromodulatory as well as immunomodulatory effects, which are transduced by -opioid receptors. In this report we show that stimulation with interleukin-4 induces -opioid receptor transcripts in human primary blood cells (T cells and polymorphonuclear leukocytes), immune cell lines (Raji, U-937, and HMEC-1), and dendritic cells. In nonstimulated immune cells this gene is silent. In addition, receptor transcription is up-regulated by interleukin-4 in cultures of primary rat neurons. Transient transfection experiments in Raji and SH SY5Y neuronal cells with human and rat reporter gene constructs linked the interleukin-4 effect directly to cis-active receptor promoter elements located at nucleotide ؊997 on the human gene and nucleotide ؊727 on the rat gene. The interleukin-4 response elements function orientation independently. They bind STAT6 transcription factors as shown by electrophoretic mobility shift assays. In the human gene, a single nucleotide polymorphism within the interleukin-4 response element reduces the trans-activating potential of this element by 50%, which may affect the phenotype of persons carrying this variation. These findings provide a molecular basis for understanding bidirectional interactions between the opioid system and the immune system.
Opioids are classically associated with phenomena such as analgesia, respiratory depression, and addiction. The effects of opioids are mediated by at least three different opioid receptors, termed , ␦, and , which belong to the G-protein-coupled membrane receptor family (1, 2) . During the last years, evidence has accumulated showing that exogenous opiates like morphine and endogenous opioid peptides derived from the precursors proopiomelanocortin, proenkephalin, and prodynorphin have multiple immunomodulatory properties in addition to their classical functions as neuromodulators. It was stated that the endogenous opioid peptides would now be considered members of the cytokine family if they had been first discovered by immunologists (3) . Elucidation of a broad bidirectional communication between the opioid system and the immune system strengthens this concept. Thus, morphine, the prototypical exogenous ligand for the receptor, is an immunosuppressive drug and is responsible for increased susceptibility of opioid addicts to infections (4 -8) . Studies with -opioid receptor knockout mice emphasized the role of this receptor in immunosuppression (9) . After chronic morphine treatment, these mice developed none of the symptoms characteristic of wild type mice, namely lymphoid organ atrophy, diminished CD4
ϩ / CD8 ϩ cell ratio and strongly reduced natural killer cell activity. In contrast, cytokines modulate the expression of opioid peptide genes and opioid receptor genes. For example, studies with IL-6 1 knockout mice revealed decreased levels of receptors in the brain compared with wild type animals, suggesting a positive regulation of this receptor by IL-6 in vivo (10) . In vitro, up-regulation of receptors was observed after IL-1 stimulation in primary astrocyte-enriched cultures derived from various brain regions (11, 12) and in neural microvascular endothelial cells (13) . In promoter studies, however, a direct activation of receptor transcription by IL-1 and IL-6 could not be demonstrated (14) .
The opioid peptide ␤-endorphin is derived from proopiomelanocortin and is a physiological endogenous ligand of the receptor. A close relationship was demonstrated between morphine and ␤-endorphin on the one hand and T cell regulation on the other. Thus, immunological effects of ␤-endorphin are exerted via activation of IL-4, the prototypical Th2 cytokine (15, 16) . In addition, morphine as well as ␤-endorphin were shown to induce a shift from a Th1-type to Th2-type cytokine pattern (8, 17) . In contrast, blocking of ␤-endorphin by antibodies or blocking of -opioid receptors by the highly specific receptor antagonist naloxone resulted in a shift from a Th2-type to Th1-type cytokine pattern (18, 19) .
Considering the apparent involvement of -opioid receptors in immunosuppression and immunomodulation, the multiple regulatory interactions between cytokines (in particular Th2 cytokines), and the -opioid system, we addressed the question of whether IL-4 may regulate expression of the -opioid receptor gene and investigated the molecular mechanisms of this regulation.
EXPERIMENTAL PROCEDURES
Cell Culture-SH SY5Y and HEK 293 cells were cultivated in Dulbecco's modified Eagle's medium (PAA Laboratories, Linz, Austria) supplemented with 15% FCS (PAA Laboratories) and antibiotics (100 units/ml penicillin and 100 mg/ml streptomycin). HMEC-1 cells were kept in endothelial growth medium EMG-2 (Clonetics, San Diego, CA) with the growth factors and supplements suggested and supplied with the medium by the manufacturer. Raji and U-937 cells were cultivated in RPMI 1640 medium (Biochrom, Berlin, Germany) supplemented with 2 mM N-acetyl-L-alanyl-L-glutamine (Biochrom), 10% FCS, and antibiotics. Human primary T cells and polymorphonuclear leukocytes were separated from blood as described previously (20) and kept in RPMI 1640 medium with 1% FCS.
Dendritic Cell Preparation-Peripheral primary human monocytes were isolated from healthy donors and differentiated into dendritic cells according to described protocols with GM-CSF (800 units/ml) and IL-4 (days 0 -2, 1000 units/ml; days 2-9, 500 units/ml) (21) (22) (23) . On the 9th day of differentiation FACS ® analysis was performed with FACscalibur (Becton Dickinson, Heidelberg, Germany). Cells were double stained with phycoerythrin-labeled CD14 and fluorescein isothiocyanate-labeled CD83 antibodies (Becton Dickinson) and checked for expression of CD83 (Ͼ80%) versus CD14 (Ͻ10%).
Preparation of Primary Cortical Neurons-Fetal cortical neurons were prepared as described previously (24) with the following modifications. In brief, 18 -19-day-old fetal rats were removed from the uterus followed by immediate preparation of their brains. The cerebral cortices were dissected and transferred to Dulbecco's modified Eagle's medium. The tissue was disassembled into single neurons using a syringe equipped with a 21-gauge 1.5-inch needle. The cells were washed twice with Dulbecco's modified Eagle's medium and plated in six-well tissue dishes coated with Matrigel (Becton Dickinson). The cells were kept for 24 h in Dulbecco's modified Eagle's medium containing 10% FCS. The cells were further cultivated for 4 days in Start V medium (Biochrom) without FCS, then stimulated, and harvested for RNA extraction.
Cytokines-Twenty-four hours prior to cytokine stimulation all cells including controls were given fresh medium with only 1% FCS to minimize interference with substances present in the serum. In all experiments, recombinant human IL-4 (R&D Systems, Wiesbaden, Germany) was used in a final concentration of 5 ng/ml, which equals ϳ150 World Health Organization units/ml for stimulation of human cells, except for differentiation of dendritic cells (see text for different concentrations). Rat cell cultures were stimulated with 5 ng/ml recombinant rat IL-4 (R&D Systems). Stock solutions of 5 g/ml in phosphatebuffered saline with 0.5% bovine serum albumin were kept at Ϫ20°C in frozen aliquots to avoid repeated freezing and thawing. Human recombinant GM-CSF was purchased from R&D Systems.
Reverse Transcription (RT)-PCR from Human Immune Effector Cells-Total
RNAs from immune cells were extracted using RNeasy columns (Qiagen, Hilden, Germany) and then checked for accidental degradation on an agarose gel. Two micrograms of total RNA were used for cDNA synthesis with Moloney murine leukemia virus reverse transcriptase, RNase H minus (Promega, Mannheim, Germany) and diluted to 100 l. To check the relative amount and the integrity 2-4 l of cDNA were used to amplify an 842-base pair fragment of the human glyceraldehyde-3-phosphate dehydrogenase gene (forward primer 5Ј-CAACTACATGGTTTACATGTTC-3Ј and reverse primer 5Ј-TGACAAC-GAATTTGGCTACAG-3Ј) under the following conditions: 25 cycles with 40 s at 94°C, 60 s at 60°C, and 180 s at 72°C. Two consecutive amplification steps were performed to amplify -opioid receptor transcripts: a first PCR with 2-5 l of cDNA (adjusted amounts that gave similar intense bands in a glyceraldehyde-3-phosphate dehydrogenase PCR) in a 30-l volume with the forward primer 5Ј-CTTGGCGTACT-CAAGTTGCT-3Ј and the reverse primer 5Ј-AATGTGAATGGGAGTC-CAGC-3Ј for 25 cycles of 40 s at 94°C, 60 s at 63°C, and 90 s at 72°C with an initial denaturation step (150 s at 94°C) and a final prolongation step (120 s at 72°C). Five microliters of the first reaction were used for a second PCR in a 30-l volume with the forward primer 5Ј-GAT-CATGGCCCTCTACTCCA-3Ј and the reverse primer 5Ј-GCATT-TCGGGGAGTACGGAA-3Ј for 30 cycles of 40 s at 94°C, 60 s at 65°C, and 90 s at 72°C with an initial denaturation step (150 s at 94°C) and a final prolongation step (120 s at 72°C). In both reactions the forward and reverse primers are located on different exons to ascertain that no genomic DNA amplification may mask the cDNA-specific amplificate. Five microliters of the second PCR were electrophoresed on a 1.5% agarose gel.
Real-time RT-PCR from Rat Neuronal Cells-Total RNA was extracted from primary neurons using TRI-Reagent (Sigma-Aldrich) following the instructions of the manufacturer. The RNA was checked on an ethidium bromide-stained agarose gel for integrity and to ensure equal amounts per sample. Four micrograms of each RNA sample were subjected to reverse transcription using TrueScript Moloney murine leukemia virus reverse transcriptase (Hybaid, Heidelberg, Germany) in a total volume of 20 l. After incubation at 42°C for 1 h the reaction mixture was diluted to 100 l, and 2 l were included in the PCR (Light Cycler-Fast Start DNA Master SYBR Green I kit, Roche Molecular Biochemicals) in a total volume of 20 l. The primers used to detect rat -opioid receptor transcript were 5Ј-CATTACCATCATGGCCCTC-TACTCTATCG-3Ј and 5Ј-ACTGGGTGGCAGACAGCAATGTAGC-3Ј yielding an amplified product of 315 base pairs. The primers spanned an intron to avoid amplification of genomic DNA. The reaction was run in a Light Cycler PCR machine (Roche Molecular Biochemicals) with a hot start preincubation step of 10 min at 95°C for 50 cycles consisting of denaturation (15 s at 95°C) and annealing/elongation (30 s at 72°C). To obtain a standard curve, the stimulated samples were pooled and serially diluted. The amount of template was quantified using the second derivative maximum method as included in the Light Cycler software package.
Construction of Reporter Plasmids-All reporter plasmids are based on the pBLCAT2/pBLCAT3 vector system (25) . The series of rat promoter reporter plasmids has been used and described previously (26) . For construction of plasmid prMORϪ1660⌬Ϫ851/Ϫ449 the basic Ϫ1660 construct was opened with SpeI (nt Ϫ617) and digested with Bal31. The enzyme was inactivated for 20 min at 80°C, and the ends were blunted with Klenow enzyme and religated. This and all other plasmids used here were sequenced, if possible from both sides, to ensure correct cloning procedures and for determination of the extent of Bal31 digests. The basic human promoter reporter plasmid (phMORϪ2229) was constructed as follows. Starting from previously cloned sequences (27) a SauI-BlpI fragment spanning from nt Ϫ2229 to nt Ϫ165 containing the prominent transcription initiation sites was inserted into the BamHI and BglII sites of the vector pBLCAT2 (25) . Simultaneously the HSV tk promoter located between these vector sites was excised. Construct phMORϪ1372 was generated by cutting the basic construct with BglII (nt Ϫ1372) and HindIII (vector), filling the ends, and religating. Construct phMORϪ779 was obtained by a 5Ј-deletion method using DNase as described previously (28) . Constructs phMORϪ2229⌬Ϫ1854/Ϫ1372 and phMORϪ2229⌬Ϫ1372/Ϫ254 were generated by cutting out fragments using the restriction enzymes AccI (nt Ϫ1854) and BglII and PstI (nt Ϫ254), blunting, and ligating. The internal deletions in the plasmids phMORϪ2229⌬Ϫ1933/Ϫ1033 and phMORϪ1372⌬Ϫ1001/Ϫ950 were made with enzyme Bal31 after opening the plasmids with BglII and NdeI (nt Ϫ985), respectively. Oligonucleotides with IL-4-responsive regions were inserted in pBLCAT2 in front of the HSV tk promoter into the XbaI (human constructs) or SphI (rat construct) sites of the vector. The sequences of the inserted human Ϫ997 wild type, human Ϫ997 polymorphic, and rat Ϫ727 oligonucleotides are given in this section under "Electrophoretic Mobility Shift Assay" since the same double-stranded oligonucleotides were used.
Transfection Experiments-The plasmid DNA used for transfection was isolated using Qiagen plasmid kits (Qiagen). Before transfection, all cells received fresh medium with 1% FCS. Transfection of SH SY5Y cells and the reporter gene assay have been described earlier (26, 29) . The same method was applied to transfect HMEC-1 and HEK 293 cells. Raji and U-937 cells were transfected as follows. Cells (5 ϫ 10 6 ) were pelleted, resuspended in 5 ml of medium, and transfected by dropwise addition of 10 g of plasmid DNA in 500 l of a buffer containing 140 mM NaCl, 25 mM Hepes, and 0.5 mM Na 2 HPO 4 (pH 7.05). After a 17-h incubation at 3% CO 2 and 35°C, cells were pelleted again and given fresh medium. After transfection, all cells were allowed to grow for a further 48 h in a 1% FCS medium containing IL-4 or vehicle prior to the CAT enzyme-linked immunosorbent assay (Roche Molecular Biochemicals).
Extraction of Nuclear Protein-Twenty-four hours prior to nuclear protein extraction SH SY5Y cells received fresh medium containing 1% FCS. Stimulation with 5 ng/ml IL-4 was for 1 h prior to nuclear protein extraction. The extraction procedure for nuclear proteins used in the electrophoretic mobility shift assays has been described in detail in a recent publication (30) .
Electrophoretic Mobility Shift Assay (EMSA)-Synthetic doublestranded oligonucleotides (Metabion, Martinsried, Germany) carrying putative STAT6 binding sites of -opioid receptor promoters and the IL-4 response element of the immunoglobulin heavy chain germline ⑀ promoter ("classic STAT6") (31) were labeled with [␥- 32 P]ATP (Amersham Pharmacia Biotech) according to standard methods (32) . For each band shift reaction 5000 cpm of labeled probe were incubated with 3 l of SH SY5Y cell nuclear extract for 15 min at room temperature in a 20-l reaction mixture containing 10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 5% glycerol, and 0.1 g of poly(dIdC) DNA. Some reactions contained additionally various amounts of competitor DNA. For immunoshift experiments 4 g of STAT6 antibody (M-20, Santa Cruz Biotechnology, Heidelberg, Germany) were added after the reaction and incubated for a further 60 min. Samples were loaded onto 6% high ionic strength polyacrylamide gels with the Trisglycine buffer system and separated electrophoretically. The gels were then dried, exposed to BAS1000 imaging plates, and analyzed by the BAS1000 phosphorimaging program. Sequences of the oligonucleotides were as follows: AP-2 motif used as unspecific competitor, 5Ј-TGCGGGCTCCCCGGGCTTGGGCGAGC-3Ј; classic STAT6, 5Ј-TAGT-CAACTTCCCAAGAACAGAATCA-3Ј; human Ϫ997 motif (wild type), 5Ј-CAACCTTCTTCTCAGAAGCATATGT-3Ј; human Ϫ997 motif (polymorphism), 5Ј-CAACCTTCTTATCAGAAGCATATGT-3Ј; rat Ϫ727 motif, 5Ј-TGTTTCCTTTCCAGAGAAAGACCATT-3Ј.
Statistical Analysis-For statistical evaluation of the transfection experiments Student's t tests were performed. Stars indicate significantly different values (*, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001). (Fig. 1A) primary human T cells and polymorphonuclear leukocytes and, in addition, the human cell lines Raji (B cells), U937 (monocytes), and HMEC-1 (microvascular endothelial cells) were used to study the effect of IL-4 on the expression of -opioid receptors in various immune effector cells. The human neuronal cell line SH SY5Y (neuroblastoma), which is known to express -opioid receptors constitutively (33) , served as positive control (Fig. 1A, lane 11) . No transcripts of -opioid receptors could be detected in any of the unstimulated immune cells (Fig. 1A, lanes 1, 3, 5, 7, and 9) . The highly sensitive nested PCR technique, which was used for these experiments, allowed us to detect as few as five copies of -opioid receptor sequences (data not shown), suggesting that in unstimulated immune cells virtually no -opioid receptor expression occurs. When the immune cells were stimulated with 5 ng/ml IL-4 for 24 h, -opioid receptor transcription was strongly induced in all cells tested (Fig. 1A, lanes 2, 4, 6, 8, and 10) .
RESULTS

Induction of -Opioid Receptor Transcripts by IL-4 in Immune Effector Cells-For a first set of experiments
In a second set of experiments -opioid receptor transcription was determined in monocytes and dendritic cells (Fig. 1B) . Peripheral monocytes were differentiated into dendritic cells with GM-CSF and IL-4 according to described methods (21, 22) . After 9 days of differentiation, the cells were morphologically mature dendritic cells with typical filopodia. FACS ® analysis during maturation revealed a reduction of CD14 expression (monocyte marker) paralleled by an induction of CD83 expression (dendritic cell marker). -Opioid receptor transcripts were detected neither in undifferentiated monocytes (Fig. 1B, lane  1) , nor in cells during maturation (i.e. after 4 days of incubation with IL-4/GM-CSF, lane 2), nor in the CD83 ϩ cells (i.e. 9 days with IL-4/GM-CSF, lane 5). This was unexpected since incubation of other immune cells with IL-4 persistently induced -opioid receptor transcription (Fig. 1A) . However, when monocytes were incubated with IL-4 alone, -opioid receptor transcripts were detected (Fig. 1B, lane 3) . When CD83 ϩ dendritic cells from day 9 were further incubated for 24 h exclusively with IL-4 (i.e. after removing the GM-CSF-containing medium) -opioid receptor transcription was also induced (Fig. 1B, lane  6) . These experiments indicate that GM-CSF inhibits -opioid receptor transcription induced by IL-4.
Regulation of -Opioid Receptor Transcripts in Primary Cortical Neurons from Rats-Cultures of primary cortical fetal neurons from rats were used to investigate whether IL-4 also had a regulatory effect on -opioid receptor transcription in cells of neuronal origin (Fig. 2) . In contrast to immune cells, receptor transcripts were already present in the neuronal cells under basal condition. Therefore, to determine quantitative changes in levels of -opioid receptor transcripts and the time course of induction by IL-4, the "real-time PCR" technique was used. This technique makes it possible to monitor the onset of the exponential phase of amplification during the PCR run. The earlier this amplification phase begins, the more template is present in the reaction. The experiments showed that IL-4 induced a transient increase in -opioid receptor transcription in the neuronal cells. About 2.7-fold increased levels of receptor transcripts were observed already after 30 min of IL-4 incubation. This peak was followed by decreasing levels of -opioid receptor transcripts, which dropped to control levels again when cells were incubated for 4 h with IL-4. (Fig. 3) . Plasmid pBLCAT2 (25) , which was used as a construction vector containing the HSV tk promoter instead of receptor promoters, showed no significant inducibility with IL-4 in all of the cells tested (Fig. 3C) . A basic construct with human upstream -opioid receptor promoter sequences contained the region spanning from nt Ϫ2229 to Ϫ165 (with respect to the first translated codon; construct phMORϪ2229) in front of the CAT reporter gene. A basic construct with the rat promoter included 5Ј-upstream sequences up to nt Ϫ1660 (construct prMORϪ1660). Stimulation of transfected cells with IL-4 (5 ng/ml) significantly elevated CAT activities for both the human (Fig. 3A) and the rat (Fig. 3B) promoter constructs in Raji, U-937, and HMEC-1 cells ϳ3-4-fold. A similar induction of receptor transcription was observed in neuronal SH SY5Y cells. In contrast, no induction after IL-4 treatment of transfected cells was found in HEK 293 cells. The latter cells are known to lack STAT6 transcription factors but contain other IL-4 signaling components (34) . Unraveling the molecular mechanisms of gene regulation by cytokines, it was found that interleukins, interferons, and growth factors induce the Janus tyrosine kinase/STAT (signal transducers and activators of transcription) signal transduction pathway (35, 36) . All STAT transcription factor family members bind to very similar cis-active elements on target gene promoters with the palindromic binding motif 5Ј-TTCn 2-4 GAA-3Ј (37). IL-4-regulated gene expression of target genes is transduced typically via STAT6 (37-41). The results obtained in HEK 293 cells thus suggest contribution of STAT6 to IL-4-mediated regulation of the -opioid receptor gene.
Inducibility of Human and Rat -Opioid Receptor Gene Promoters by IL-4 -Transient
Localization of IL-4-responsive Promoter Elements-Raji and SH SY5Y cells were used for further transfection experiments with deletion constructs containing various lengths of 5Ј-flanking regions of the -opioid receptor promoters to localize promoter elements required for IL-4 inducibility. The conclusions that can be drawn from the experiments with respect to IL-4 inducibility are identical for both Raji and SH SY5Y cells. Therefore, in the following text it was not discriminated between the two cell types; however, results for both cells are shown separately in the figures. The human promoter contains three motifs of the sequence 5Ј-TTCn 2-4 GAA-3Ј with three central nucleotides, which may serve as binding sites for the STAT6 transcription factor, located at nt Ϫ1583, Ϫ1061, and Ϫ997 (Fig. 4A) . When the longest construct with all putative STAT6 binding motifs (lane 1, construct phMORϪ2229) was shortened at its 5Ј-end deleting the most distal Ϫ1583 putative STAT6 motif, IL-4 inducibility was retained (lane 2, construct phMORϪ1372). A construct with a further 5Ј-deletion up to nt Ϫ779, in which the remaining two STAT6 motifs also were deleted, showed no stimulation (lane 3, construct phMORϪ779). Constructs with internal deletions were made to test which motif(s) mediate IL-4 stimulation of reporter gene expression. As expected from the above results, a construct in which only sequences containing the distal Ϫ1583 motif were deleted was still responsive to IL-4 (lane 4, construct phMORϪ2229⌬Ϫ1854/Ϫ1372). A construct in which the Ϫ1061 motif was additionally deleted was also responsive to IL-4 (lane 5, construct phMORϪ2229⌬Ϫ1933/Ϫ1033), indicating that the proximal motif may be involved. This was indeed true since deletion of the proximal motif at nt Ϫ997 abolished the IL-4 effect (lane 6, construct phMORϪ2229⌬Ϫ1372/Ϫ254 and lane 7, construct phMORϪ1372⌬Ϫ1001/Ϫ950). Taken together, the transfection experiments with the human promoter demonstrated that a region spanning from nt Ϫ950 to nt Ϫ1001, which contains the proximal putative STAT6 motif at nt Ϫ997, is sufficient to mediate the IL-4 stimulatory effect.
Like the human promoter, the rat -opioid receptor promoter also contains three putative STAT6 binding sites located at nt Ϫ1353, Ϫ982, and Ϫ727 with two, three, and four central nucleotides, respectively (Fig. 4B) . Transfection of a series of 5Ј-deletion constructs of the rat promoter suggests that, like in the human gene, sequences around the proximal putative STAT6 motif (nt Ϫ727) are necessary for IL-4 induction of this promoter. Thus, neither deletion of the distal motif (lane 2, construct prMORϪ1198) nor the additional deletion of the middle motif (lane 3, construct prMORϪ974) affected IL-4 responsiveness of the reporter gene constructs. When the proximal motif also was deleted, the IL-4 effect was abolished (lane 4, construct prMORϪ605). A construct with an internal deletion of sequences around the proximal motif showed no inducibility (lane 5, construct prMORϪ1660⌬Ϫ851/Ϫ449). Taken together, these experiments showed that sequences of the rat promoter spanning from nt Ϫ605 to nt Ϫ851, which contain the proximal putative STAT6 motif at nt Ϫ727, are sufficient to mediate the IL-4 effect.
Oligonucleotides containing the proximal motifs were then cloned in front of the tk promoter in pBLCAT2 to test whether they are sufficient to mediate IL-4 responsiveness (Fig. 4C) . The human Ϫ997 (lane 1) and the rat Ϫ727 (lane 3) motif both conferred IL-4 responsiveness to the heterologous tk promoter independently of the orientation (lanes 2 and 4 show the constructs with the motifs cloned in the antisense orientation), demonstrating that these sequences are sufficient to mediate IL-4 induction of the -opioid receptor gene.
The IL-4-responsive Promoter Elements Bind STAT6 Transcription Factors-Using the EMSA technique, the IL-4-responsive elements of the human and rat -opioid receptor gene promoters were characterized. Incubation of an oligonucleotide probe containing the IL-4 response element of the immunoglobulin heavy chain germline ⑀ gene promoter (termed classic STAT6 oligonucleotide) with nuclear proteins isolated from IL-4-stimulated SH SY5Y cells resulted in a pattern similar to that shown originally by Delphin and Stavnezer (31) . Of the two prominent low mobility complexes C1 and C2, C1 has been identified as the specific IL-4-inducible complex (31) (Fig. 5, A and B, lanes 2). A kinetic experiment showed that complex C1 was induced maximally after 30 min to 2 h of IL-4 treatment of cells prior to nuclear protein extraction (data not shown). The C1 complex, and to a lesser extend also C2, were competed by the homologous classic STAT6 oligonucleotide (A and B, lanes 4 and 5), but not unspecifically by an AP-2 oligonucleotide (, A and B, lanes 3) derived from the ␦-opioid receptor (42) . Human Ϫ997 oligonucleotides (Fig. 5A, lanes 6 and 7) and also rat Ϫ727 IL-4 motif oligonucleotides (B, lanes 6 and 7) were as effective in competition as classic STAT6 oligonucleotides themselves, indicating that the same nuclear factors bind to these sequences. In contrast, when oligonucleotides containing the -opioid receptor IL-4 response elements were used as probes, EMSA patterns similar to those obtained with classic STAT6 oligonucleotides were obtained (A and B, lanes 8) , and the specific complexes were competed by classic STAT6 oligonucleotides (A and B, lanes 9 and 10) . Supershift experiments directly demonstrated binding of this factor to -opioid receptor IL-4-responsive elements of both species. Thus, using a specific STAT6 antibody, the IL-4-inducible complex C1 disappeared (A  and B, lanes 11 and 12) . To a lesser extend, complex C2 also is affected by the STAT6 antibodies, indicating that it may also contain small amounts of STAT6 protein.
A Single Nucleotide Polymorphism in the Human IL-4-responsive Element Decreases IL-4 Inducibility-Recently the human -opioid receptor gene has been studied for sequence variability among 250 individuals revealing at least 43 variants within the gene (43) . More than half of these, 28, were found in the 5Ј-regulatory region. Interestingly, one such naturally occurring sequence variation in the promoter region leads to a single nucleotide exchange within the Ϫ997 IL-4 response element. Thus, the wild type sequence 5Ј-TTCTcA-GAA-3Ј is changed into 5Ј-TTaTcAgAA-3Ј, interrupting its palindromic structure (throughout this report, palindromic nucleotides within IL-4 response elements/STAT6 motifs are shown in uppercase). Therefore, both alleles were compared to reveal whether the polymorphism changes the trans-activation potential of the motif and/or binding of STAT6. Transfection of the mutated allele (Fig. 6A, lanes 3 and 4) resulted in a dramatically decreased IL-4 response compared with the human wild type sequence (Fig. 6A, lanes 1 and 2) . On the other hand, EMSAs comparing the wild type and the mutated motifs revealed no difference in binding to STAT6. Thus, both motifs were equally effective competitors for complex C1 using the classic STAT6 probe (Fig. 6B) . Additionally, despite their markedly different trans-activating potentials, the polymorph motif as a probe gave similar EMSA patterns as the wild type motif, and supershift experiments demonstrated STAT6 binding to the mutated motif as well (Fig. 6C) .
DISCUSSION
Earlier studies demonstrated immunosuppressive and immunoregulatory functions of opioid alkaloids like morphine and endogenous opioid peptides such as ␤-endorphin (5, 8, 15, 19) . ␤-Endorphin has been considered as a neuropeptide as well as a Th2 cytokine (44) . In the present study we have shown that -opioid receptors, for which ␤-endorphin and morphine are ligands, are induced by the Th2 cytokine IL-4 in native immune cells, immune cell lines, dendritic cells, and primary neuronal cells. The IL-4 signal is directly transduced to the receptor gene promoter via STAT6.
The multiple effects of opioids on immune effector cells obtained from functional studies implicate that opioid receptors are expressed on these cells (4, 9, 19, 45, 46) . However, data obtained from different laboratories are rather contradictory when receptor transcripts were attempted to be demonstrated directly. Thus, -opioid receptor transcripts were detected in lymphocytes, monocytes, and macrophages by some researchers (47, 48) , whereas other groups failed to detect receptor expression but consistently showed ␦-and -opioid receptor expression in immune cells (49, 50) . Our experiments showed that -opioid receptor expression in immune effector cells strongly depends on cytokine stimulation. Thus, variations in cytokine concentrations present in cell culture medium may be an explanation for different results by different groups. The results of the experiments with dendritic cells suggested that other cytokines may also regulate receptor expression since the IL-4 effect was inhibited by GM-CSF. Regulation of the -opioid receptor gene by other cytokines is currently being investigated and will be the focus of future communications.
Transcriptional effects of cytokines on selected genes often occur indirectly because of cascade-like induction of secondary cytokines. Direct transcriptional activation of target genes by IL-4 is transduced typically via the transcription factor STAT6 (38) . The IL-4-responsive elements of the human and rat -opioid receptor gene promoters are STAT6 binding sites. The human element contains three central nucleotides ("N3 motif") and the rat element contains four ("N4 motif") between the two halves of the palindrome 5Ј-TTCn 2-4 GAA-3Ј. Both element have, independent of their orientation, similar strong transactivating potentials as demonstrated by experiments with the heterologous HSV tk promoter. A single nucleotide exchange within the Ϫ997 IL-4 response element, which occurs as a genetic variation in humans, changes the sequence 5Ј-TTC . . . GAA-3Ј into 5Ј-TTa . . . gAA-3Ј (43) . Although binding of STAT6 to the mutated sequence is not notably different compared with STAT6 binding to the wild type motif, the trans-activating potential of this sequence is markedly reduced to about 50% compared with the wild type. The following observations may help to explain this discrepancy despite our limited knowledge about the mechanisms of STAT6-mediated transcriptional activation. On the one hand, in vitro studies using a variety of DNA probes that contain the 5Ј-TTCn 2-4 GAA-3Ј motif together with randomly chosen nucleotides in the center and outside the palindrome revealed that N4 motifs bind STAT6 with higher affinity than N3 motifs (34, 39) . On the other hand, it was demonstrated in the same studies that the same N4 motifs that bound STAT6 were not responsive to IL-4 in transfection ex- periments (34, 39) . Thus, binding of STAT6 to a 5Ј-TTCn 2-4GAA-3Ј motif does not necessarily mean that this motif also has trans-activating potential in response to IL-4. Therefore, it may not be astonishing that the mutated human Ϫ997 element binds STAT6 with similar affinity as the wild type element despite a reduced trans-activating potency. Moreover, binding of other STAT proteins to the palindromic sequence consisting only of 5Ј-TTn 4 -6 AA-3Ј also occurs in other genes responding to cytokines as listed by Decker and colleagues (37) . IL-4/STAT6-induced transcription may require the interaction between multiple transcription factors as demonstrated for the murine germline ⑀ gene promoter, where an N4 STAT6 motif is adjacent to a CCAAT/enhancer-binding protein motif, and both factors are necessary for transcriptional activation from this promoter (31) . Predicted from their sequences, -opioid receptor promoter sequences that confer IL-4 induction are unlikely to bind other transcription factors. Alternatively, co-activators of transcription that mediate between STAT6 and the general transcriptional machinery may be necessary, similar to CREBinduced transcription mediated via the CREB-binding protein CBP (51) . Among naturally occurring IL-4-responsive sequences, the motif of the low affinity IgE receptor (CD23b) is an N3 motif in which the palindromic halves are extended: 5Ј-TTTCTaAGAAA-Ј3 (52) . Interestingly, the IL-4 response elements of the -opioid receptors from both species are also symmetrically extended, whereas all the other 5Ј-TTCn 2-4GAA-3Ј motifs of these genes, which were not involved in IL-4 regulation, consisted only of the minimal palindrome. The human IL-4-responsive element is 5Ј-CTTCTcAGAAG-3Ј, and the rat motif is 5Ј-CTTTCcagaGAAAG-3Ј. This observation suggests a possible functional importance of palindromic nucleotides immediately adjacent to the 5Ј-TTC-3Ј and 5Ј-GAA-3Ј sequences for trans-activation. In the future, identification of additional response elements on other IL-4-responsive genes and comparison of their sequences will be required to reveal a more precise structure-function relationship.
A challenge in the "post-genomic era" will be elucidation of functional allelic variations with defined molecular effects. Among the variants of the human -opioid receptor gene, those found in the 5Ј-regulatory region may be of remarkable functional importance if they affect transcriptionally regulatory motifs as demonstrated here for IL-4 response elements. It will be interesting to correlate this polymorphism to a certain phenotype. To date, however, the number of individuals known to carry this variation is too low for such studies (43) . With respect to genes of the opioid system, we reported earlier on a functional polymorphism within the prodynorphin gene promoter, which consists of a repeat containing an AP-1 transcription factor site. The number of this repeat varies among individuals as does the response of the promoter to stimuli of AP-1 (53) .
IL-4 may also be involved in the regulation of -opioid receptor expression in neuronal cells. Increasing information about IL-4 and its receptors in brain suggests the importance of this cytokine in the neuronal environment (54, 55) . It was shown that high levels of IL-4 are present in the brains of neonatal mice (56) . It may be interesting in this context that high levels of STAT6 were also found in developing brains and that they were localized to regions that abundantly express receptors, namely hippocampus, striatum, and cortex (57), suggesting a possible role of IL-4 in developmental regulation of receptor expression. In general, it should be considered that changes in IL-4 concentrations within the central nervous system may potentially affect the effectivity of analgesic drugs by modulating the number of -opioid receptors. Recently changes in IL-4 and/or IL-4 receptor levels associated with distinct cerebral diseases such as Parkinson's disease (58) and brain ischemia (59) were demonstrated. Likewise, the approved drug copolymer 1, which is used for treatment of multiple sclerosis, exerts its effects via activation of Th2 cytokines including IL-4 (60) . Knowledge about regulatory stimuli of receptor genes for pharmacologically important ligands would be of more than academic interest if either such stimuli were used to induce the expression of drug receptors to achieve a better effect of the ligand or if the effect of such stimuli could help to explain the side effects of a drug.
